As our clinical trials progress with increasing global footprint, our clinical-stage products have also received continuous recognition from our partners as we are granted with impressive payment or are entitled to co-developed late-stage products with Nasdaq-listed partners. The globalized efforts of clinical research and business development will also prepare GenFleet for a globalized strategy of commercialization in advance.
Staff with Master or Doctoral Degrees
GenFleet sets up a cutting-edge pipeline of innovative therapies with a view to our prospective and highly differentiated strategy: we basically choose biological targets or pathways that have not achieved proof of concept in clinical trials across the globe. Our proprietary and fully integrated R&D platform and diversified co-development programs promote the company's continuous innovative drug discovery and clinical progress.
As our clinical trials progress with increasing global footprint, our clinical-stage products have also received continuous recognition from our partners home and abroad. The globalized efforts of clinical research and business development will also prepare GenFleet for a globalized strategy of commercialization in advance.
It’s the first China-developed KRAS G12C inhibitor that has its NDA submission accepted and granted with Priority Review Designation by NMPA. GFH925 also received Breakthrough Therapy Designations this year for treating advanced KRAS G12C-mutant NSCLC that have received at least one systemic therapy and colorectal carcinoma (CRC) patients who have received at least two systemic therapies.
The phase I, multi-center trial of GFH009 monotherapy for r/r hematological malignancies has completed its dose escalation portion in both China and the US. Clinical trials of GFH009 demonstrated significant reduction in expression of proto-oncogenes such as MYC, MCL1 among patients with hematological malignancies including PTCL. Four PTCL patients（36.4%）were observed with clinical response including one in a continuous treatment for over 56 weeks. GenFleet has started its phase Ib/II trial of G
Preliminary results from GFH009 monotherapy study for relapsed/refractory hematological malignancies demonstrated favorable safety/tolerability of GFH009 with no unexpected dose limiting toxicities or hematological toxicities difficult to determine in patients. With regard to efficacy, the study exhibited GFH009’s anti-tumor activity of up to 77.3% bone marrow blast reduction and desired levels of MCL1 & MYC suppression in peripheral blood with decrease in MCL1 or MYC observed in 97% (66/68)